GO:0030971 receptor tyrosine kinase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030971 receptor tyrosine kinase binding is a molecular function defined as binding to a receptor that possesses protein tyrosine kinase activity.
• Ligand binding to the extracellular domain of receptor tyrosine kinases (RTKs) is the primary mechanism that drives receptor dimerization and activation.
• RTK activation involves conformational changes, oligomerization, and trans-autophosphorylation of intracellular kinase domains.
• Dysregulated RTK binding and activation are central to many cancers, including ALK-rearranged lung cancer and AXL-driven kidney cancer.
• Key genes mediating this function include EGFR, ALK, AXL, MET, and RON, which are major therapeutic targets.
• CRISPR-based knockout, point mutation, and knock-in models are essential for dissecting RTK binding specificity and downstream signaling.
Description
Receptor tyrosine kinase binding (GO:0030971) is a molecular function that describes the binding of a protein or ligand to a receptor possessing protein tyrosine kinase activity. This interaction is a fundamental step in cell signaling, enabling cells to respond to extracellular cues such as growth factors, hormones, and cytokines. The binding event typically occurs at the extracellular domain of the receptor, leading to receptor dimerization or oligomerization and subsequent activation of the intracellular kinase domain. Understanding this function is critical for researchers studying signal transduction, cancer biology, and developmental processes. The QuickGO definition states that this term encompasses binding to any receptor with protein tyrosine kinase activity, including transmembrane receptors that are themselves kinases. This broad definition covers a wide range of ligand-receptor interactions, from growth factor binding to EGFR to cytokine binding to receptors like RON. As RTK signaling is frequently dysregulated in human diseases, particularly cancer, the study of receptor tyrosine kinase binding has become a cornerstone of biomedical research.
receptor tyrosine kinase binding At A Glance
| GO ID | GO:0030971 |
|---|---|
| GO term | receptor tyrosine kinase binding |
| Ontology | molecular_function |
| Synonym | transmembrane receptor protein tyrosine kinase ligand binding |
| Definition | Binding to a receptor that possesses protein tyrosine kinase activity. |
| Major function | Mediates ligand-induced activation of receptor tyrosine kinases, initiating intracellular signaling cascades. |
| Related receptors | EGFR, ALK, AXL, MET, RON, and other RTKs. |
| Disease relevance | Cancer, developmental disorders, and inflammatory diseases. |
What Is GO:0030971?
In simple terms, GO:0030971 receptor tyrosine kinase binding refers to the physical interaction between a molecule (often a ligand) and a receptor that has the ability to add phosphate groups to tyrosine residues on proteins. This binding event is the first step in a signaling cascade that can control cell growth, division, and survival. The official definition from QuickGO is: Binding to a receptor that possesses protein tyrosine kinase activity. The synonym transmembrane receptor protein tyrosine kinase ligand binding highlights that many of these receptors span the cell membrane and bind extracellular ligands.
Why Is receptor tyrosine kinase binding Important in Cell Biology?
Receptor tyrosine kinase binding is a central node in cellular communication, and its dysregulation is a hallmark of many human diseases, especially cancer. The binding event determines the specificity and intensity of downstream signaling, influencing processes such as proliferation, differentiation, and survival. Because RTKs are often mutated or overexpressed in tumors, understanding the molecular details of ligand-receptor binding is essential for developing targeted therapies, including monoclonal antibodies and small molecule inhibitors. Moreover, recent studies have revealed complex regulatory mechanisms, such as hetero-interactions between different RTKs and nuclear translocation of receptors like RON, expanding the scope of this function beyond the plasma membrane.
• RTK binding is the first step in many growth factor signaling pathways that control cell fate.
• Mutations and fusions in RTKs, such as ALK, are driver events in multiple cancers.
• The binding affinity and kinetics between ligand and receptor can determine signaling outcomes.
• RTK hetero-interactions can modulate signaling specificity and are emerging as therapeutic targets.
• Optical methods to measure RTK oligomerization provide insights into activation mechanisms.
• Nuclear translocation of RTKs like RON adds a layer of complexity to RTK function.
• Pseudokinase domains in RTKs can regulate binding and activation, offering new research directions.
• AXL stability and its impact on immune response highlight the role of RTK binding in tumor microenvironment.
• CRISPR screens can identify novel regulators of RTK binding and signaling.
• Targeting RTK binding interfaces is a promising strategy for drug development.
What Happens During receptor tyrosine kinase binding?
Ligand recognition and binding
In simple terms: A ligand molecule attaches to the outside part of a receptor on the cell surface.
The process begins when a specific ligand, such as a growth factor, binds to the extracellular domain of a receptor tyrosine kinase. This binding is highly specific and is governed by the structural complementarity between the ligand and the receptor's ligand-binding domain. For example, the binding of growth factors to EGFR family receptors induces a conformational change that exposes dimerization arms. The affinity and kinetics of this interaction are critical for determining the strength and duration of the signal.
Receptor dimerization and oligomerization
In simple terms: Two or more receptors come together after the ligand binds, which turns them on.
Ligand binding typically promotes receptor dimerization or higher-order oligomerization. This brings the intracellular kinase domains into close proximity, allowing them to phosphorylate each other in trans. The oligomerization state can vary among RTKs; some form stable dimers, while others form transient oligomers. Optical measurement techniques have been used to visualize RTK oligomerization on live cells, revealing dynamic assembly processes. Hetero-interactions between different RTK family members can also occur, adding complexity to the signaling output.
Kinase activation and trans-autophosphorylation
In simple terms: The receptors add phosphate groups to each other, which switches on their signaling activity.
Once dimerized, the kinase domains of RTKs undergo trans-autophosphorylation on specific tyrosine residues within the activation loop and other regulatory regions. This phosphorylation stabilizes the active conformation of the kinase and creates docking sites for downstream signaling proteins containing SH2 or PTB domains. The activation process is tightly regulated and can be influenced by the presence of pseudokinase domains in some RTKs, which lack catalytic activity but can still regulate signaling.
Downstream signaling initiation
In simple terms: The activated receptor sends signals inside the cell by recruiting other proteins.
Phosphorylated tyrosines on the activated RTK serve as binding sites for adaptor proteins and enzymes, such as GRB2, PLC-gamma, and PI3K. These interactions initiate multiple signaling cascades, including the MAPK/ERK and PI3K/AKT pathways, which control gene expression, metabolism, and cell survival. The specific set of downstream effectors recruited depends on the particular RTK and the cellular context, leading to diverse biological outcomes.
Receptor internalization and trafficking
In simple terms: After signaling, the receptor is taken into the cell to be recycled or degraded.
Following activation, RTKs are often internalized via clathrin-mediated endocytosis. This process can either attenuate signaling by targeting receptors for degradation or sustain signaling from endosomal compartments. Recent studies have also revealed that some RTKs, such as RON, can translocate to the nucleus, where they may have additional functions. The trafficking of RTKs is a key regulatory step that determines the duration and spatial aspects of signaling.
Key Genes Involved in GO:0030971 receptor tyrosine kinase binding
The following genes encode receptors or ligands that participate in receptor tyrosine kinase binding (GO:0030971) and are frequently studied in cancer and signaling research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Binds EGF and related ligands; activates MAPK and PI3K pathways | Mutated in lung cancer; target of tyrosine kinase inhibitors |
| ALK | Binds ALKAL ligands; involved in neuronal development | Fusions in lung cancer and neuroblastoma; target of crizotinib |
| AXL | Binds GAS6; regulates cell survival and immune response | Overexpressed in kidney cancer; linked to mesenchymal phenotype |
| MET | Binds HGF; controls cell motility and proliferation | Mutations in lung cancer and papillary renal carcinoma |
| RON | Binds MSP; regulates macrophage function and epithelial cell growth | Nuclear translocation linked to cancer progression |
| FGFR1 | Binds FGF ligands; regulates development and angiogenesis | Amplified in breast cancer and glioblastoma |
| FGFR2 | Binds FGF ligands; involved in bone and limb development | Mutations in craniosynostosis and endometrial cancer |
| FGFR3 | Binds FGF ligands; regulates bone growth | Mutations in achondroplasia and bladder cancer |
| FGFR4 | Binds FGF ligands; regulates bile acid synthesis | Overexpressed in liver cancer |
| IGF1R | Binds IGF1 and IGF2; promotes growth and survival | Target in sarcoma and breast cancer |
| INSR | Binds insulin; regulates glucose metabolism | Mutations in diabetes and insulin resistance |
| PDGFRA | Binds PDGF; regulates mesenchymal cell growth | Mutations in gastrointestinal stromal tumors |
| PDGFRB | Binds PDGF; regulates vascular development | Mutations in leukemia and myofibromatosis |
| KIT | Binds stem cell factor; regulates hematopoiesis | Mutations in gastrointestinal stromal tumors and melanoma |
| VEGFR2 | Binds VEGF; regulates angiogenesis | Target in anti-angiogenic cancer therapy |
| ERBB2 | Binds heregulin; forms heterodimers with EGFR | Amplified in breast and gastric cancer |
| ERBB3 | Binds heregulin; kinase-dead but signals via heterodimers | Implicated in breast and colorectal cancer |
| ERBB4 | Binds heregulin; regulates neuronal development | Mutations in melanoma and schizophrenia |
How Is receptor tyrosine kinase binding Regulated?
The binding of ligands to receptor tyrosine kinases is tightly regulated at multiple levels. Ligand availability, receptor expression levels, and the presence of decoy receptors or soluble ligand traps can modulate the interaction. Post-translational modifications, such as glycosylation and phosphorylation, can affect receptor conformation and binding affinity. Additionally, hetero-interactions between different RTKs can alter ligand specificity and signaling output. Recent studies have highlighted the role of pseudokinase domains in regulating RTK activation, acting as switches or scaffolds. Furthermore, the stability of RTKs like AXL is controlled by ubiquitination and deubiquitination, influencing the pool of receptors available for binding. Nuclear translocation of RON adds another layer of regulation, where the receptor may interact with nuclear proteins.
receptor tyrosine kinase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALK | Non-small cell lung cancer, neuroblastoma | Knockout of ALK in cancer cell lines; point mutation of fusion kinase |
| AXL | Kidney renal clear cell carcinoma, immune evasion | Overexpression of AXL in kidney cells; knockout to assess mesenchymal phenotype |
| RON | Cancer progression, macrophage function | Knock-in of nuclear localization signal; knockout in macrophages |
| FGFR2 | Craniosynostosis, endometrial cancer | Point mutation of ligand-binding domain; knock-in mouse models |
| EGFR | Lung cancer, glioblastoma | Knockout of EGFR in cancer cells; overexpression of mutant EGFR |
Cancer
Dysregulated receptor tyrosine kinase binding and activation are hallmarks of many cancers. Activating mutations, gene amplifications, and chromosomal rearrangements can lead to ligand-independent activation or hypersensitivity to ligands. For example, ALK fusions in non-small cell lung cancer result in constitutive kinase activity, driving tumor growth. Overexpression of AXL in kidney renal clear cell carcinoma is associated with a mesenchymal phenotype and poor immune response. Targeting RTK binding with monoclonal antibodies or small molecule inhibitors has proven successful in the clinic, but resistance often emerges, necessitating new strategies.
Developmental disorders
RTK signaling is critical for embryonic development, and mutations in RTKs or their ligands can cause developmental syndromes. For instance, mutations in FGFR2 are linked to craniosynostosis syndromes, while FGFR3 mutations cause achondroplasia. These mutations often affect ligand binding affinity or receptor dimerization, leading to altered signaling during bone and limb formation. Understanding the molecular basis of these defects can inform therapeutic approaches.
Inflammatory and immune disorders
RTKs such as RON and AXL play roles in immune cell function and inflammation. RON is expressed on macrophages and regulates their activation and cytokine production. AXL is involved in the resolution of inflammation and immune evasion in tumors. Dysregulation of these receptors can contribute to chronic inflammatory diseases and autoimmune conditions. Targeting RTK binding in immune cells is an emerging area of research.
From receptor tyrosine kinase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RTK binding affect downstream signaling? | CRISPR knockout of the receptor gene in cell lines |
| How does a specific point mutation alter ligand binding affinity? | CRISPR point mutation knock-in of the receptor |
| Can a tagged receptor be used to track binding dynamics? | Knock-in of fluorescent or epitope tag at the endogenous locus |
| What is the effect of receptor overexpression on cell proliferation? | CRISPR overexpression via safe-harbor integration |
| Which genes regulate RTK binding and activation? | Genome-wide CRISPR library screening |
| How does a disease-associated mutation affect receptor function? | Knock-in of the mutation in isogenic cell lines |
How to Study the receptor tyrosine kinase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| FRET | Receptor oligomerization and conformational changes | Live-cell imaging of RTK activation |
| Cryo-EM | High-resolution structure of ligand-receptor complexes | Drug design and mechanistic studies |
| CRISPR knockout screening | Genes required for RTK signaling | Identification of novel therapeutic targets |
| Phosphoproteomics | Global phosphorylation changes upon RTK activation | Mapping signaling pathways |
| Surface plasmon resonance | Binding affinity and kinetics of ligand-receptor interactions | Characterization of RTK-ligand pairs |
| Immunoprecipitation | Protein-protein interactions involving RTKs | Identification of binding partners |
| RNA-seq | Transcriptional changes downstream of RTK activation | Gene expression profiling |
Optical measurement of RTK oligomerization
Advanced optical techniques, such as fluorescence resonance energy transfer (FRET) and single-molecule imaging, allow real-time visualization of RTK oligomerization on live cells. These methods can quantify the extent and dynamics of receptor clustering following ligand binding, providing insights into activation mechanisms.
Structural biology of RTK-ligand complexes
X-ray crystallography and cryo-electron microscopy have elucidated the atomic details of ligand binding to RTK extracellular domains. These structures reveal the specific interactions that confer ligand specificity and drive receptor dimerization, informing drug design.
CRISPR screening for regulators of RTK signaling
Genome-wide CRISPR knockout or activation screens can identify genes that modulate RTK binding and downstream signaling. Such screens have uncovered novel regulators of RTK stability, trafficking, and hetero-interactions.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can map the phosphorylation events that occur after RTK activation and identify downstream effectors. This approach provides a global view of signaling networks initiated by receptor tyrosine kinase binding.
How CRISPR Can Be Used to Study GO:0030971 receptor tyrosine kinase binding
Knockout
CRISPR knockout of a receptor tyrosine kinase gene can completely abolish its binding function, allowing researchers to study its role in signaling and disease. For example, knocking out AXL in kidney cancer cells can reverse mesenchymal phenotype and enhance immune response. Knockout models are also useful for validating drug targets and understanding compensatory mechanisms.
Point Mutation
Introducing specific point mutations in the ligand-binding domain or kinase domain of an RTK can mimic disease-associated mutations or disrupt binding. This approach helps dissect the contribution of individual residues to ligand binding affinity and specificity. For instance, point mutations in FGFR2 can recapitulate craniosynostosis phenotypes.
Knock-in
Knock-in of tagged receptors (e.g., GFP or HA) at the endogenous locus enables real-time tracking of receptor expression, localization, and binding dynamics. This technique preserves endogenous regulatory elements, providing physiological relevance. Knock-in of disease mutations in isogenic cell lines is also powerful for studying pathogenesis.
Overexpression
CRISPR-mediated overexpression of an RTK or its ligand can model gene amplification or ligand excess observed in cancers. Overexpression models are valuable for studying dose-dependent effects on signaling and for screening drugs that target RTK binding. Safe-harbor integration ensures consistent expression levels.
How EDITGENE Supports receptor tyrosine kinase binding Research
Researchers studying receptor tyrosine kinase binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. This requires precise genetic manipulation to avoid confounding effects from off-target changes or overexpression artifacts. EDITGENE provides a comprehensive suite of CRISPR-based services to support such investigations, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for receptor tyrosine kinase binding research.
Frequently Asked Questions About receptor tyrosine kinase binding
What is GO:0030971 receptor tyrosine kinase binding?
GO:0030971 is a Gene Ontology molecular function term defined as binding to a receptor that possesses protein tyrosine kinase activity. It encompasses the interaction between ligands and receptor tyrosine kinases, initiating signaling cascades.
What genes are involved in receptor tyrosine kinase binding?
Key genes include EGFR, ALK, AXL, MET, RON, FGFR1-4, IGF1R, INSR, PDGFRA/B, KIT, VEGFR2, and ERBB2/3/4. These encode receptors that bind specific ligands and activate downstream pathways.
How does receptor tyrosine kinase binding lead to cancer?
Dysregulated binding, such as overexpression or mutations that cause ligand-independent activation, can lead to constitutive signaling that drives cell proliferation and survival, contributing to cancer development.
What are the therapeutic targets in receptor tyrosine kinase binding?
Therapeutic strategies include monoclonal antibodies that block ligand binding, small molecule inhibitors that target the kinase domain, and decoy receptors that sequester ligands.
How can CRISPR be used to study receptor tyrosine kinase binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of RTK genes to study their role in binding and signaling.
What methods measure receptor tyrosine kinase binding?
Methods include surface plasmon resonance, FRET, cryo-EM, and phosphoproteomics, each providing different insights into binding affinity, structural changes, and downstream signaling.
What is the role of ALK in receptor tyrosine kinase binding?
ALK binds ALKAL ligands and is involved in neuronal development. ALK fusions are oncogenic drivers in lung cancer and neuroblastoma, making it a key therapeutic target.
How does AXL contribute to kidney cancer?
AXL overexpression in kidney renal clear cell carcinoma is associated with mesenchymal phenotype and immune evasion. Its stability is regulated by STAMBPL1/TRIM21, impacting tumor progression.
Can receptor tyrosine kinases translocate to the nucleus?
Yes, some RTKs like RON can undergo nuclear translocation, where they may have additional functions beyond plasma membrane signaling.
What are pseudokinase domains in RTKs?
Pseudokinase domains are structurally similar to kinase domains but lack catalytic activity. They can regulate RTK activation and binding through allosteric mechanisms.
Conclusion
Receptor tyrosine kinase binding (GO:0030971) is a fundamental molecular function that governs cellular responses to growth factors and cytokines. Its dysregulation is implicated in a wide range of diseases, particularly cancer, making it a prime target for therapeutic intervention. Advances in structural biology, live-cell imaging, and CRISPR-based genetic models continue to unravel the complexities of RTK binding and activation. Researchers equipped with these tools can dissect the precise molecular events that drive signaling and identify new strategies to modulate RTK function in disease.
References
- 1. Du Z et al.. 2018. Mechanisms of receptor tyrosine kinase activation in cancer.. Mol Cancer 17(1):58 PMID: 29455648
- 2. Trenker R et al.. 2020. Receptor tyrosine kinase activation: From the ligand perspective.. Curr Opin Cell Biol 63:174-185 PMID: 32114309
- 3. Hallberg B et al.. 2016. The role of the ALK receptor in cancer biology.. Ann Oncol 27 Suppl 3:iii4-iii15 PMID: 27573755
- 4. Smith AW et al.. 2025. Regulation of receptor tyrosine kinase hetero-interactions.. Curr Opin Struct Biol 95:103187 PMID: 41232168
- 5. Chung I. 2017. Optical measurement of receptor tyrosine kinase oligomerization on live cells.. Biochim Biophys Acta Biomembr 1859(9 Pt A):1436-1444 PMID: 28389201
- 6. Chen YL et al.. 2025. Nuclear translocation of RON receptor tyrosine kinase. New mechanistic and functional insights.. Cytokine Growth Factor Rev 81:9-15 PMID: 39794156
- 7. Sheetz JB et al.. 2020. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.. Mol Cell 79(3):390-405.e7 PMID: 32619402
- 8. Huang S et al.. 2025. STAMBPL1/TRIM21 Balances AXL Stability Impacting Mesenchymal Phenotype and Immune Response in KIRC.. Adv Sci (Weinh) 12(1):e2405083 PMID: 39527690
